Nivolumab for Patients with IDH-Mutant Gliomas

A study for adults with recurrent IDH1 or IDH2 mutated gliomas.

Objective

National Cancer Institute (NCI) researchers are conducting a study of patients with IDH-mutated gliomas.

This study will test whether stimulating the immune system using the drug nivolumab can shrink recurrent IDH-mutant gliomas with and without hypermutator phenotype or increase the time it takes for them to grow or spread.

What the study involves:

- Full physical and neurological examination
- Health and symptoms questionnaire
- MRIs and laboratory tests
- Study of tumor tissue from prior surgeries
- Receive drug nivolumab for up to 20 treatments over 64 weeks
- Your samples used for genetic and biomarker testing
- Visits every month during treatment and 28, 60, 100 days after treatment
- Monitoring calls every six months after treatment
- All tests, procedures and medications provided at no cost

You can participate if you:

- Are age 18 or older
- Are diagnosed with a glioma with IDH1 or IDH2 mutation that has returned
- Do not have hepatitis
- Are not pregnant or breastfeeding

You can participate in this study by visiting the NIH at Bethesda, Maryland, for a clinical assessment.

Questions?

Contact us at (240) 760-6010 or NCINOBReferrals@mail.nih.gov

clinicaltrials.gov ID: NCT03718767